Drug Profile
BI 2536
Alternative Names: BI 2536 BS; BI-2536Latest Information Update: 07 Oct 2014
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Benzamides; Piperidines; Pteridines; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 07 Oct 2014 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV) (NCT02211833)
- 24 Sep 2014 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (IV)
- 24 Sep 2014 Discontinued - Phase-I for Solid tumours in Germany (IV-infusion)